Antiviral Drug Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The antiviral drug manufacturing industry in the European Union comprises the industrial-scale synthesis and preparation of antiviral medicaments used to treat viral infections such as HIV, hepatitis, influenza, and coronaviruses. The industry is highly technical and closely linked to the broader pharmaceutical manufacturing sector, which recorded a massive trade surplus of €221 billion in 2025 according to Eurostat. Driven by robust clinical pipelines and regional manufacturing resilience strategies, the sector is increasingly focused on developing advanced small-molecule antivirals and monoclonal antibodies while expanding local production capacities to secure supply chains against emergin

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Antiviral Drug Manufacturing in European Union industry cover?

This industry involves the formulation, manufacturing, and packaging of antiviral pharmaceutical preparations designed to inhibit the replication of viruses within human hosts. It encompasses both small-molecule chemical entities and complex biological therapeutics, including monoclonal antibodies, engineered for specific viral targets. Production processes range from the synthesis of Active Pharmaceutical Ingredients (APIs) to primary and secondary formulation into finished dosage forms like tablets, capsules, and injectables.

• •Covers medicaments targeted at chronic viral conditions like HIV-1 and Hepatitis C, as well as acute respiratory viruses.
• •Falls within the broader European statistical classification of manufacturing medicinal and pharmaceutical products.
• •Excludes generic chemical wholesale distribution, focusing exclusively on industrial scaling and Good Manufacturing Practice (GMP) compliant formulation.

Who operates in the industry and how is it structured?

The EU market is characterized by a mix of research-based multinational corporations operating advanced local facilities and contract development and manufacturing organizations (CDMOs). Industrial clusters are heavily concentrated in western and central European Member States, which maintain strong clinical ecosystems and advanced logistical infrastructure. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the wider research-based pharmaceutical sector directly employed an estimated 955,000 individuals in Europe in 2025.

• •Major manufacturing hubs are situated across Germany, France, Italy, Ireland, and Belgium.
• •Operators heavily utilize specialized CDMOs to optimize fill-finish capabilities and scale up production during viral epidemics.
• •European facilities supply both the intra-EU public healthcare systems and global export markets, heavily interfacing with international regulatory standards.

What drives demand in the industry?

The demand for antiviral drug manufacturing in the EU is primarily driven by public health procurement, shifting epidemiological patterns, and an aging population vulnerable to viral pathogens. National reimbursement frameworks and stockpile initiatives by individual Member States ensure consistent demand for critical therapies against seasonal influenza and chronic viral infections. Furthermore, regional trade expansion supports production, as evidenced by a 16% growth in the EU's total medicinal and pharmaceutical product exports in 2025.

• •Persistent clinical demand exists for cutting-edge antiretroviral therapies (ART) for long-term management of HIV.
• •The Health Emergency Preparedness and Response Authority (HERA) stimulates systemic demand through joint EU procurement and strategic stock initiatives.
• •Growing global reliance on European-manufactured pharmaceuticals expanded the total extra-EU trade surplus in this category to €221 billion in 2025.

Who are the notable companies in the industry?

Competition within the EU antiviral manufacturing sector centers on proprietary innovation, patent portfolios, and the technical competence required for complex biological synthesis. Multinational entities lead the market by leveraging vast capital to fund local European production sites alongside specialized chemical enterprises. Notable public corporations with substantial manufacturing and operational presence in the EU include Sanofi SA, Roche Holding AG, GlaxoSmithKline plc, and Merck KGaA.

• •Sanofi SA maintains extensive active ingredient synthesis and formulation facilities across several EU member nations.
• •Roche Holding AG drives advanced biotechnology manufacturing, supplying critical viral diagnostics and therapeutics from European sites.
• •GlaxoSmithKline plc operates global manufacturing centers in the EU, producing key antiviral treatments through its specialized therapeutic divisions.
• •Merck KGaA provides vital life-science manufacturing components, raw materials, and specialized API processing facilities across Germany and Western Europe.

What are the recent trends and outlook?

The industry is experiencing a strategic pivot toward digitalizing manufacturing lines and adopting continuous manufacturing technologies to increase yield and reduce operational footprints. High capital deployment continues across the continent, with the research-based pharmaceutical sector investing an estimated €60.0 billion in R&D in Europe during 2025. Moving forward, the industry is adjusting to localized 'near-shoring' initiatives aimed at mitigating reliance on third-country supply chains for basic chemical precursors.

• •Accelerated investment in automation and AI-driven quality control across European manufacturing lines.
• •Increased focus on mRNA-based platforms and therapeutic modifications for rapid-response antiviral scalability.
• •The top five EU markets experienced an average market growth rate of 8.4% during the 2020-2025 period according to IQVIA data published by EFPIA.

How is the industry regulated?

Manufacturing facilities operating in the EU are subject to some of the strictest regulatory oversight frameworks globally, managed by the European Medicines Agency (EMA) and national competent authorities. Companies must rigorously comply with EU Good Manufacturing Practice (GMP) directives to guarantee the safety, purity, and tracking of all produced lots. Additionally, the industry is adapting to revamped legislative packages aimed at streamlining drug approvals while mandating stricter environmental and supply-chain transparency.

• •Mandatory adherence to Directive 2001/83/EC and subsequent amendments governing medicinal products for human use.
• •Strict oversight of API imports and production localization under the European Union's updated Pharmaceutical Strategy.
• •Compliance with the Falsified Medicines Directive (Directive 2011/62/EU) requires serialisation and end-to-end verification features on all prescription packaging.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat International Trade in Medicinal and Pharmaceutical Products 2025 ·
• EFPIA The Pharmaceutical Industry in Figures 2026 ·
• European Medicines Agency (EMA) Manufacturing Authorisation Guidelines ·
• European Commission Directorate-General for Health and Food Safety